



Antibody-Based Therapeutics Against COVID-19

Guest Editor:

Prof. Dr. Rui Gong

Center for Antiviral Research,
Wuhan Institute of Virology (WIV),
Chinese Academy of
Sciences, 262 Jinlong Street,
Jiangxia, Wuhan 430207, China

Deadline for manuscript
submissions:

closed (20 September 2021)

Message from the Guest Editor

Dear Colleagues,

An emerging coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes the disease known as COVID-19. To date, SARS-CoV-2 continues to rapidly spread globally and seriously threaten public health. Therapeutic antibodies are shown to be very effective in the treatment of various diseases, including viral infection and immune disorder. Clinical trials with antibody-based drugs for COVID-19 are being performed all over the world. Some of them are quite promising. For example, Bamlanivimab, a neutralizing antibody against SARS-CoV-2, was authorized by the FDA for the treatment of COVID-19 in high-risk patients on November 9, 2020. This Special Issue will collect the last progress on antibody-based therapeutics against COVID-19 from bench to bedside.

Prof. Dr. Rui Gong
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: CiteScore - Q1 (*Drug Discovery*)

Contact Us

Antibodies
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
 @Antibodies_MDPI